LONDON Cambridge Antibody Technology Group plc said that Peter Chambré, former chief operating officer of Celera Genomics Inc., will become chief executive officer when the company’s founder, David Chiswell, retires in April.

Chambré is credited with helping transform Celera from an informatics company to a drug discovery and development company. He was responsible for the acquisition of Axys Pharmaceuticals Inc. Prior to that he was CEO for six years of Bespak plc, a supplier of drug delivery technology and systems for inhaled therapeutics.

CAT, based in Melbourn, said in November 2001 that Chiswell would leave once a successor was in place. The company said that taking it forward to becoming profitable required a different skill set than running an R&D-focused start-up.

Peter Garland, CAT’s chairman, said, “We are delighted that Peter has agreed to join CAT at this time when the company is positioning itself for transition to a profitable biopharmaceutical business.” Nuala Moran